Electronic Arts (NASDAQ:EA) is set to report its fiscal 2018 fourth-quarter earnings on May 8, after the market close.
Thanks to the popularity of the Ultimate Team digital card game, EA has been seeing strong engagement in its flagship sports titles, FIFA and Madden NFL. During the fourth quarter, EA launched esports events for both games that are designed to bring in more players to the base, to drive growth in digital revenue. So investors will be very interested to hear what management has to say about how these efforts are working.
Here's what to watch:
IMAGE mage source: EA.com.
Will FIFA and Madden deliver?Superdata's March video game sales report once again showed FIFA 18 and Madden NFL 18 ranked among the top 10 games on console in digital spending. Both games were released more than seven months ago, and the NFL season is well over, which makes this latest sales report especially significant.
Top 5 Heal Care Stocks To Buy Right Now: Lantronix, Inc.(LTRX)
Advisors' Opinion:- [By Joseph Griffin]
Lantronix (NASDAQ:LTRX) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday.
- [By Stephan Byrd]
Echelon (NASDAQ: ELON) and Lantronix (NASDAQ:LTRX) are both small-cap computer and technology companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, institutional ownership, dividends and analyst recommendations.
- [By Joseph Griffin]
Lantronix Inc (NASDAQ:LTRX)’s share price reached a new 52-week high during trading on Monday . The stock traded as high as $4.03 and last traded at $3.90, with a volume of 768 shares trading hands. The stock had previously closed at $3.85.
- [By Ethan Ryder]
Lantronix (NASDAQ:LTRX) shares hit a new 52-week high and low during mid-day trading on Thursday . The stock traded as low as $3.24 and last traded at $3.20, with a volume of 2090 shares traded. The stock had previously closed at $3.21.
Top 5 Heal Care Stocks To Buy Right Now: Merit Medical Systems Inc.(MMSI)
Advisors' Opinion:- [By Max Byerly]
Merit Medical Systems, Inc. (NASDAQ:MMSI) has been assigned a consensus recommendation of “Buy” from the fourteen brokerages that are presently covering the company, Marketbeat.com reports. Thirteen research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $52.00.
- [By Ethan Ryder]
Get a free copy of the Zacks research report on Merit Medical Systems (MMSI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Motley Fool Transcribing]
Merit Medical Systems (NASDAQ:MMSI) Q2 2018 Earnings Conference CallJul. 23, 2018 5:00 p.m. ET
Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:Operator
Top 5 Heal Care Stocks To Buy Right Now: Cytosorbents Corporation(CTSO)
Advisors' Opinion:- [By Stephan Byrd]
Get a free copy of the Zacks research report on Cytosorbents (CTSO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Ethan Ryder]
Wells Fargo & Company MN boosted its holdings in Cytosorbents Co. (NASDAQ:CTSO) by 182.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 20,929 shares of the medical research company’s stock after purchasing an additional 13,515 shares during the period. Wells Fargo & Company MN owned about 0.07% of Cytosorbents worth $136,000 at the end of the most recent reporting period.
- [By Ethan Ryder]
Cytosorbents Corp (NASDAQ:CTSO) COO Vincent Capponi sold 9,565 shares of the company’s stock in a transaction that occurred on Tuesday, August 28th. The shares were sold at an average price of $13.00, for a total value of $124,345.00. Following the completion of the transaction, the chief operating officer now owns 342,333 shares in the company, valued at approximately $4,450,329. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Top 5 Heal Care Stocks To Buy Right Now: Calamos Convertible and High Income Fund(CHY)
Advisors' Opinion:- [By Max Byerly]
Calamos Convertible & Hi Income Fund (NASDAQ:CHY) was the target of a large growth in short interest in September. As of September 14th, there was short interest totalling 705,860 shares, a growth of 35.5% from the August 31st total of 521,121 shares. Approximately 1.0% of the company’s stock are short sold. Based on an average daily volume of 212,797 shares, the days-to-cover ratio is currently 3.3 days.
- [By Shane Hupp]
Calamos Convertible & Hi Income Fund (NASDAQ:CHY) declared a monthly dividend on Monday, February 4th, Wall Street Journal reports. Stockholders of record on Tuesday, February 12th will be given a dividend of 0.085 per share by the investment management company on Wednesday, February 20th. This represents a $1.02 annualized dividend and a dividend yield of 9.32%. The ex-dividend date of this dividend is Monday, February 11th.
Top 5 Heal Care Stocks To Buy Right Now: Foamix Pharmaceuticals Ltd.(FOMX)
Advisors' Opinion:- [By Stephan Byrd]
Press coverage about Foamix Pharmaceuticals (NASDAQ:FOMX) has trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Foamix Pharmaceuticals earned a news impact score of 0.14 on Accern’s scale. Accern also assigned press coverage about the specialty pharmaceutical company an impact score of 45.4298608245084 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
- [By Ethan Ryder]
News headlines about Foamix Pharmaceuticals (NASDAQ:FOMX) have trended somewhat positive recently, Accern reports. Accern rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Foamix Pharmaceuticals earned a news impact score of 0.15 on Accern’s scale. Accern also assigned press coverage about the specialty pharmaceutical company an impact score of 48.1562748121044 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
- [By Joseph Griffin]
Headlines about Foamix Pharmaceuticals (NASDAQ:FOMX) have been trending somewhat positive recently, according to Accern. The research group rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Foamix Pharmaceuticals earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave news headlines about the specialty pharmaceutical company an impact score of 47.5479155329096 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
- [By Joseph Griffin]
Foamix Pharmaceuticals (NASDAQ:FOMX)‘s stock had its “buy” rating reiterated by HC Wainwright in a report issued on Wednesday, MarketBeat reports. They currently have a $14.00 price objective on the specialty pharmaceutical company’s stock, up from their prior price objective of $12.00. HC Wainwright’s price objective would indicate a potential upside of 122.22% from the stock’s current price.
- [By Chris Lange]
Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) shares were last seen up early on Wednesday after the company announced a solid performance in its late-stage trial for moderate-to-severe acne.
- [By Max Byerly]
HC Wainwright set a $11.00 price target on Foamix Pharmaceuticals (NASDAQ:FOMX) in a research note released on Tuesday. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.
No comments:
Post a Comment